

Pegaptanib sodium

Cat. No.:	HY-109561
CAS No.:	222716-86-1
Sequence:	RNA, ((2'-deoxy-2'-fluoro)C-Gm-Gm-A-A-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-A m-Gm-(2'-deoxy-2'-fluoro)U-Gm-Am-Am-(2'-deoxy-2'-fluoro)U-Gm-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)U-Am-(2'-deoxy-2'-fluoro)C-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)C-(2'-deoxy-2'-fluoro)C-Gm-(3'-OH)-dT, 5'-ester with 5'-[4,12-dioxo-6-[[[5-(phosphonoxy)pentyl]amino]carbon yl]-3,13-dioxo-5,11-diaza-1,15-pentadecanediy]bis[2-methoxypoly(oxy-1,2-ethanediy l)], sodium salt
Target:	VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	-20°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Pegaptanib (sodium)

BIOLOGICAL ACTIVITY

Description	Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) [1].
In Vitro	Pegaptanib also inhibits VEGF165-mediated phosphorylation of VEGFR2 and phospholipase C γ and inhibited VEGF165-induced calcium mobilization in human umbilical vein endothelial cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Eugene W M Ng, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006 Feb;5(2):123-32.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA